Overview of the Collaboration

Atropos Health, a company specializing in converting real-world clinical data (RWD) into actionable evidence, has announced a strategic partnership with Ontada, a McKesson business focused on community oncology.

Objectives of the Partnership

• Enhance the use cases for clinicians, researchers, and healthcare leaders.
• Facilitate the design of care protocols.
• Promote precision medicine.
• Develop new treatment options in oncology.

Technological Integration

Atropos Health will implement its GENEVA OS, an operating system designed for rapid healthcare evidence generation, into the internal cloud data environments of its customers. This integration will allow:

• Access to longitudinal patient data from various sources within the Atropos Evidence Network.
• Deidentified patient records while maintaining data security and ownership.
• Query capabilities on RWD to evaluate specific questions through the Real-World Fitness Score.

Recent Innovations

This partnership follows Atropos Health’s recent announcement regarding the Federated Nodal Deidentification Technology, which will be incorporated into the GENEVA OS platform. This technology enables users to address data gaps in patients’ longitudinal records.

Statements from Leadership

Brigham Hyde, CEO and co-founder of Atropos Health, emphasized the ongoing demand for high-quality data in oncology, stating:

“The Atropos Evidence Network, which will now include Ontada’s RWD, provides benefits across the entire healthcare ecosystem. For health systems, the oncology multi-modal network contains the high-quality RWD necessary to generate the RWE needed for high-stakes clinical decisions.”

Context of the Collaboration

This partnership is part of a broader trend in which Atropos Health has been actively collaborating with various organizations:

1. In February, Atropos partnered with Emory Healthcare to enhance medication formulary decisions and protocols.
2. In January, Atropos collaborated with xCures to utilize AI for real-world evidence insights.
3. Also in January, Atropos joined forces with Merck to generate RWE and provide rapid insights on real-world data.

Funding and Growth

In 2024, Atropos Health secured $33 million in Series B funding, led by Valtruis, with participation from new investors such as McKesson Ventures and Merck GHI Fund, as well as existing investors.

Expansion of Offerings

Atropos Health also welcomed Arcadia, a healthcare data analytics company, into its health portfolio, allowing Arcadia’s users access to Atropos’ applications for clinical decision-making in value-based care.